If you made any changes in Pure these will be visible here soon.

Research Output 1988 2020

Filter
Review article
2020

Epidemiology and surveillance for hepatocellular carcinoma: New trends

Singal, A. G., Lampertico, P. & Nahon, P., Feb 2020, In : Journal of Hepatology. 72, 2, p. 250-261 12 p.

Research output: Contribution to journalReview article

Hepatocellular Carcinoma
Epidemiology
Eastern Africa
Far East
alpha-Fetoproteins
2019

Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B

Voulgaris, T., Papatheodoridi, M., Lampertico, P. & Papatheodoridis, G. V., Jan 1 2019, (Accepted/In press) In : Liver International.

Research output: Contribution to journalReview article

Open Access
Chronic Hepatitis B
Hepatocellular Carcinoma

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Hepatitis Delta International Network (HDIN), Yurdaydin, C., Abbas, Z., Buti, M., Cornberg, M., Esteban, R., Etzion, O., Gane, E. J., Gish, R. G., Glenn, J. S., Hamid, S., Heller, T., Koh, C., Lampertico, P., Lurie, Y., Manns, M., Parana, R., Rizzetto, M., Urban, S. & Wedemeyer, H., May 1 2019, In : Journal of Hepatology. 70, 5, p. 1008-1015 8 p.

Research output: Contribution to journalReview article

Chronic Hepatitis D
Hepatitis D
Hepatitis Delta Virus
Virus Diseases
Biomarkers

Update of the statements on biology and clinical impact of occult hepatitis B virus infection

Taormina Workshop on Occult HBV Infection Faculty Members, Aug 1 2019, In : Journal of Hepatology. 71, 2, p. 397-408 12 p.

Research output: Contribution to journalReview article

Open Access
Virus Diseases
Hepatitis B virus
Education
2018

Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?

Viganò, M., Loglio, A., Grossi, G. & Lampertico, P., Feb 1 2018, In : Expert Review of Anti-Infective Therapy. 16, 2, p. 153-161 9 p.

Research output: Contribution to journalReview article

Tenofovir
Chronic Hepatitis B
Safety
Therapeutics
Prodrugs

Treatment of hepatitis B: Is there still a role for interferon?

Viganò, M., Grossi, G., Loglio, A. & Lampertico, P., Feb 1 2018, In : Liver International. 38, p. 79-83 5 p.

Research output: Contribution to journalReview article

Hepatitis B
Interferons
Hepatitis B Surface Antigens
Tenofovir
Therapeutics
2017

Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs)

Grossi, G., Viganò, M., Loglio, A. & Lampertico, P., Jan 1 2017, In : Liver International. 37, p. 45-51 7 p.

Research output: Contribution to journalReview article

Hepatitis B virus
Tenofovir
Antiviral Agents
Fibrosis
Hepatocellular Carcinoma
2016

Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients

Lampertico, P., Chan, H. L. Y., Janssen, H. L. A., Strasser, S. I., Schindler, R. & Berg, T., Jul 1 2016, In : Alimentary Pharmacology and Therapeutics. 44, 1, p. 16-34 19 p.

Research output: Contribution to journalReview article

Tenofovir
Nucleosides
Hepatitis B virus
Nucleotides
Lactic Acidosis
2015

Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer?

Ayoub, W. S., Martin, P. & Lampertico, P., Jan 1 2015, In : Current Hepatitis Reports. 14, 4, p. 279-283 5 p.

Research output: Contribution to journalReview article

Liver Neoplasms
Hepatitis B
Hepatocellular Carcinoma
Incidence
Far East